Clazosentan failed to prevent clinical deterioration as a result of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage in the phase 3 REACT trial.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - February 6, 2023 Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the
Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
Idorsia Pharmaceuticals Ltd: Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained.